MedTrace Logo

A Study to Evaluate Next Day Effects of MK-4305 on Driving Performance (MK-4305-035 AM1)

NCT01311882 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2016-02-22

No results posted yet for this study

Summary

This is a study to evaluate next-day residual effects of MK-4305 on highway driving performance in healthy, non-elderly participants.

Conditions

Interventions

DRUG

MK-4305 40 mg

4 x 10 mg MK-4305 tablets

DRUG

MK-4305 20 mg

2 x 10 mg MK-4305 tablets

DRUG

Zopiclone

1 x 7.5 mg Zopiclone tablet

DRUG

Grossly Matching Placebo for Zopiclone

Grossly Matching Placebo for Zopiclone

DRUG

Matching Placebo for MK-4305

Matching Placebo for MK-4305

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
21 Years
Max Age
64 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2011-04-30
Primary Completion
2011-11-30
Completion
2011-11-30

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01311882 on ClinicalTrials.gov